South Texas Alzheimer’s Disease Center Biomarker Core

南德克萨斯阿尔茨海默病中心生物标志物核心

• 批准号: 10662331
• 负责人: Xianlin Han
• 金额: $ 10.25万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10662331
• 关键词: Alzheimer' s Disease; Alzheimer' s disease related dementia; Amyloid; Basic Science; Biochemical; Biological Assay; Biological Markers; Biology; Blood; Brain; Capsicum; Caring; Catalogs; Cerebrovascular Trauma; Clinical; Clinical Research; Clinical Trials; Cognition; Collaborations; Collection; Communication; Communities; DNA; Data; Dementia; Development; Diagnosis; Differential Diagnosis; Disease; Doctor of Philosophy; Early Diagnosis; Endothelium; Enrollment; Exclusion Criteria; Feces; Functional disorder; Funding; Genomics; Goals; Grant; Heterogeneity; Hispanic; Hispanic Populations; Image; Individual; International; Link; Magnetic Resonance Imaging; Measures; Metabolic; Methods; Molecular; Motor; Nerve Degeneration; Neurosciences; Non-Insulin-Dependent Diabetes Mellitus; Onset of illness; Participant; Patient Recruitments; Patients; Pattern; Persons; Plasma; Population; Positron-Emission Tomography; Prevalence; Procedures; Process; Protocols documentation; RNA; Research Personnel; Resources; Saliva; Sampling; Sensory; Serum; Services; South Texas; System; Time; Translational Research; Visit; Work; biobank; biomarker development; biomarker identification; clinical center; clinical diagnosis; cohort; data management; disease heterogeneity; disorder subtype; flexibility; fluorodeoxyglucose positron emission tomography; follow-up; genomic data; improved; inflammatory marker; insight; lipidomics; metabolomics; monocyte; multiple omics; neurodegenerative dementia; neuropathology; normal aging; novel; novel marker; peripheral blood; personalized medicine; pre-clinical; prodromal Alzheimer' s disease; prognostication; repository; research study; risk prediction; symposium

Biomarkers permit a deeper understanding of biology, improve risk prediction, diagnosis and prognostication at pre-clinical and clinical stages of Alzheimer Disease and Related Disorders (ADRD). The overall goals of the Biomarker core (BC) are two-fold: (1) To provide ante-mortem biobanking services for STAC, that is to collect and store biospecimens for all persons enrolled in the Clinical Core (patients, care partners and controls), an estimated 265/year at their initial and annual follow-up visits, and similarly collect and store biospecimens for persons not enrolled in the CC but referred by another STAC core (e.g. population core study enrollees, clinical trial patients, brain bank donors) and working with the Data, Statistical Management and Administrative Cores catalog, track and share these samples. (2) To identify biomarkers for detecting preclinical ADRD, for risk prediction of progression to MCI and ADRD dementia, and for differential diagnosis and identifying subtypes of ADRD MCI and dementia. The BC is led by Xianlin Han, PhD, a leader in AD metabolomics/lipomics and Mini Jacob, MD, PhD, studying sensory-motor biomarkers in ADRD. We have added Co-I Sara Espinoza, MD, a senior geriatrician who is Director of the GRECC and Pepper Center Clinical Core. To achieve these goals: Firstly, we will collect, process, store, share and track biospecimens (serum, plasma, peripheral blood monocytes, DNA, RNA, CSF and saliva or stool when indicated), as well as non-invasive sensorimotor measures from individuals and link to their clinical, imaging, genomic and neuropathologic data. We will use the latest biochemical and molecular methods and apply best practice procedures. Secondly, we will validate or identify biomarkers among the Hispanic population by collaborating with the CC, PNC, GMC, IC and NPC to correlate the markers with clinical diagnoses, course of disease, imaging and neuropathology. We will make these data publicly available by submitting samples and curated data to repositories such as NACC, NCRAD and NIAGADS. Thirdly, we will identify novel CSF and plasma metabolic biomarkers in individuals with Suspected Non-Alzheimer Pathophysiology (SNAP) with or without type 2 diabetes mellitus (T2DM). In collaboration with the CC, PNC and IC we will identify individuals with SNAP with and without T2DM (300-400 in total, half T2DM at rate of ~80/year), identify plasma metabolic biomarkers distinguishing between classical biomarker-defined AD (A+/T+/N+) and SNAP in persons with and without T2DM. We expect to find a unique biomarker and metabolic signature in SNAP compared to AD and in SNAP with T2DM that will help us better understand the biology of SNAP and may help with diagnosis and treatment. In summary, BC will collect and share biospecimens, and generate and share extensive biomarker data in Hispanics to establish a unique resource for understanding the heterogeneity of ADRD in South Texas and for development of AD personalized treatments.

生物标志物允许对生物学有更深入的了解，改善风险预测，诊断和预后 阿尔茨海默氏病和相关疾病的临床前和临床阶段（ADRD）。总体目标 生物标志物核心（BC）有两个折叠：（1）为Stac提供前验尸生物库服务，即 收集和存储所有参与临床核心的人（患者，护理伙伴和 对照组），估计在初次和年度随访时估计为265/年，同样收集和存储 未参加CC的人的生物测量，而是由另一个Stac核心提及（例如，人口核心研究 参与者，临床试验患者，脑库捐助者）以及使用数据，统计管理和 行政核心编目，跟踪和共享这些样本。 （2）识别用于检测的生物标志物 临床前ADRD，用于预测向MCI和ADRD痴呆的风险预测，以及用于鉴别诊断 并确定Adrd MCI和痴呆症的亚型。卑诗省由广告领导者Xianlin Han，博士领导 代谢组学/脂肪组学和Mini Jacob，医学博士，博士，研究ADRD的感觉运动生物标志物。我们有 GRECC和Pepper Center临床主任，添加了Co-I Sara Espinoza，医学博士，医学博士 核。为了实现这些目标：首先，我们将收集，处理，存储，共享和跟踪生物测量 （指示时血清，血浆，外周血单核细胞，DNA，RNA，CSF和唾液或粪便）以及 非侵入性感觉运动测量来自个体，并与其临床，成像，基因组和 神经病理数据。我们将使用最新的生化和分子方法，并采用最佳实践 程序。其次，我们将通过 与CC，PNC，GMC，IC和NPC合作，以将标记与临床诊断相关联 疾病，成像和神经病理学。我们将通过提交样本和 策划了NACC，NCRAD和NIAGADS等存储库的数据。第三，我们将确定新颖的CSF和 怀疑非alzheimer病理生理学（SNAP）的个体中的血浆代谢生物标志物（SNAP） 有或没有2型糖尿病（T2DM）。与CC，PNC和IC合作，我们将确定 带有和不带T2DM的SNAP的个体（总计为300-400，T2DM为〜80/年），识别等离子体 代谢生物标志物区分经典的生物标志物定义的AD（A+/T+/N+）和人的捕捉 有和没有T2DM。我们希望与 广告和与T2DM的快照，这将有助于我们更好地了解SNAP的生物学，并可能有助于 诊断和治疗。总而言之，卑诗省将收集和共享生物测量，并生成和分享 西班牙裔中广泛的生物标志物数据建立了一种独特的资源来理解的异质性 在德克萨斯州南部的ADRD和开发广告个性化治疗方法。